The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles
Abstract
Blocking the HER2 signaling pathway has been an effective strategy in the treatment of HER2‐positive breast cancer. It mainly relies on the use of monoclonal antibodies and tyrosine‐kinase inhibitors. Herein, we present a new strategy, the nano molecularly imprinted polymer (nanoMIP). The nanoMIPs, imprinted using HER2 N‐glycans, could bind almost all HER2 glycans and suppress the dimerization of HER2 with other HER family members, blocking the downstream signaling pathways, thereby inhibiting HER2+ breast cancer growth. In vitro experiments demonstrated that the nanoMIPs specifically targeted HER2+ cells and inhibited cell proliferation by 30 %. In vivo experiments indicated that the mean tumor volume of the nanoMIP‐treated group was only about half of that of the non‐treated groups. This study provides not only a new possibility to treat of HER2+ breast cancer but also new evidence to boost further development of nanoMIPs for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302594110 · Cited by 169
Cited by
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Advanced bioactive nanomaterials for biomedical applications
Zhao, Y., Zhang, Z., Pan, Z., & Liu, Y. (2021) · Exploration · doi:10.1002/exp.20210089 · Cited by 357
Molecularly Imprinted Polymers for Cell Recognition
Piletsky, S., Canfarotta, F., Poma, A., Bossi, A. M., & Piletsky, S. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.10.002 · Cited by 278
Metadata
- Authors
- Dong, Y., Li, W., Gu, Z., Xing, R., Ma, Y., Zhang, Q., & Liu, Z.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2019-06-28
- Volume
- 58
- Issue
- 31
- Pages
- 10621-10625
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2954615912
- Cited by
- 194
- References
- 4
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles. https://app.cochat.ai/papers/10.1002/anie.201904860
- The paper
- Dong, Y., Li, W., Gu, Z., Xing, R., Ma, Y., Zhang, Q., & Liu, Z. (2019). Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.201904860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.